Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Importation, Pay-For-Delay Reform Backed By Biden Order; March-In Rights For Pricing Suggested

Executive Summary

The policies have long been Democratic priorities, but of the three, the order’s implicit support for march-in rights might lead to the biggest change.

You may also be interested in...



Drug Pricing Reform: Now It Is HHS Secretary Becerra’s Turn

After months of reticence about his Administration's plans for tackling drug pricing, Biden's executive order offers some clues about what might be in store and what kind of timeline they are working with. 

Trump’s Legacy Versus ‘March In’ Rights

Biden’s incoming Secretary of Health is a fan of ‘march in’ rights as a cost-containment tool for medicines. Two hold-overs from Trump Presidency may slow him down.

Biden’s HHS Pick Sought ‘March In’ Rights For Veklury; Targeted AbbVie ‘Pay For Delay’ Tactics

California attorney general Xavier Becerra has sought to lower drug prices in California as part of a broader focus on health care costs, an approach he may bring to a new role in the Biden Administration.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144700

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel